Heart Failure With Preserved Ejection Fraction Clinical Trials in Dallas, Texas

6 studies are recruiting for heart failure with preserved ejection fraction in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Cedar Health Research, LLC, Dallas, Texas

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

   This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

   Stage

   Phase 2

   Ages

   30 to 84

   Site

   Local Institution - 167, Dallas, Texas

   Locations

   25 in total

   Run by

   Edgewise Therapeutics, Inc.

   See if you can join NCT07795814 on ClinicalTrials.gov

3. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Baylor Scott and White Research Institute, Dallas, Texas

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov

4. Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

   The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contrib…

   Stage

   Not phased

   Ages

   55 to 90

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT05723679 on ClinicalTrials.gov

5. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

   Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will no…

   Stage

   Phase 3

   Ages

   50 to 99

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   78 in total

   Run by

   Uppsala University

   See if you can join NCT02901184 on ClinicalTrials.gov

6. Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

   The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are: * safety and tolerability of the gene therapy; and * whether the gene therapy…

   Stage

   Phase 1

   Ages

   50 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   2 in total

   Run by

   Sardocor Corp.

   See if you can join NCT06061549 on ClinicalTrials.gov